Deborah Toppmeyer

9.9k citations
87 papers · 7.4k · 6 hit papers · h-index 30

Impact in

    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics
  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • Cancer-related Molecular Pathways

Papers in

    • Breast Cancer Treatment Studies 32
    • Cancer Treatment and Pharmacology 10
    • Cancer Immunotherapy and Biomarkers 6
    • Drug Transport and Resistance Mechanisms 3
    • Cancer-related Molecular Pathways 3

Deborah Toppmeyer

80 papers receiving 7.3k citations

Deborah Toppmeyer's Hit Papers

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 2022 · 329 citations
3290+6+13Years since publication5001k1.5k

Peers

Deborah Toppmeyer
Comparison fields: 5 of 108
  • Cancer Research 4k
  • Oncology 1.6k
  • Genetics 612
  • Pulmonary and Respiratory Medicine 427
  • Health Informatics 31
Replace Maccon Keane with:
Maccon Keane Ireland
Chungyeul Kim South Korea
Richard B. Schwab United States
Pär‐Ola Bendahl Sweden
Della Makower United States
Caroline A. Lohrisch Canada
Jeremy P. Braybrooke United Kingdom
Hagen Fritz Kennecke Canada
Dimitrios Zardavas Belgium
Lisa Rydén Sweden
Deborah Toppmeyer relative to Maccon Keane Ireland Maccon Keane's profile →
Citations per field
00.5×1.5×2×2.3×
Maccon Keane · 1×
Citations per year

Countries citing papers authored by Deborah Toppmeyer

Since Specialization
Citations

This map shows the geographic impact of Deborah Toppmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Toppmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Toppmeyer more than expected).

Fields of papers citing papers by Deborah Toppmeyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Toppmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Toppmeyer. The network helps show where Deborah Toppmeyer may publish in the future.

Co-authors

The 25 scholars most cited alongside Deborah Toppmeyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deborah Toppmeyer Line = papers co-authored together Deborah Toppmeyer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Hit paper breakdown →
20181708
2
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Hit paper breakdown →
20151040
3
Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
Hit paper breakdown →
2006928
4
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Hit paper breakdown →
2018540
5
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Hit paper breakdown →
2019391
6
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Hit paper breakdown →
2022329
7 2006255
8 2015178
9 2017167
10 2019122
11 2021119
12 1994112
13 2020104
14 202092
15 201787
16
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
199580
17 201475
18 200471
19
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
200269
20 201958

About Deborah Toppmeyer

Deborah Toppmeyer is a scholar working on Cancer Research, Oncology, Genetics, Molecular Biology and Statistics and Probability, having authored 87 papers that have together received 7.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (32 papers), BRCA gene mutations in cancer (16 papers), Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (3 papers), Drug Transport and Resistance Mechanisms (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cancer Research (4k citations), Oncology (1.6k citations), Genetics (612 citations), Pulmonary and Respiratory Medicine (427 citations) and Health Informatics (31 citations). Deborah Toppmeyer has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Bruce George Haffty, Thomas J. Kearney, Qifeng Yang, Joanne Barnes Weidhaas, Lyndsay N. Harris, Susan A. Higgins, Michael Reiß, Eric P. Winer, Hope S. Rugo and Kim Marie Hirshfield. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Frontiers in Oncology, Annals of Oncology and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact